预约演示
更新于：2025-05-15
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2025-05-15
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
76
项与 复方布洛芬 相关的临床试验CTRI/2025/03/083300
Comparative evaluation of effect of pre-emptive oral medication of ibuprofen-paracetamol combination, and an oral enzymatic complex on the anesthetic efficacy of inferior alveolar nerve block in children with symptomatic irreversible pulpitis: A prospective, double-blind, randomized clinical trial - NIL
CTIS2024-519661-22-00
- FMLD-UMBRIA-62
CTR20244277
对乙酰氨基酚布洛芬片在健康受试者中单中心、随机、开放、单剂量、交叉空腹和餐后状态下的生物等效性试验
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
9
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Liu, Sun Mei ; Park, Grace ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-10-01Clinical therapeutics4区 · 医学
Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial
4区 · 医学
Article
作者: Atkinson, Hartley C ; Stanescu, Ioana ; Gottlieb, Ira J ; Daniels, Stephen E ; Playne, Rebecca ; Zhang, Jennifer
PURPOSE:
Multimodal analgesia with acetaminophen and/or nonsteroidal anti-inflammatory drugs is recommended for the treatment of postoperative pain. Although oral fixed-dose combinations (FDCs) are available, parenteral administration may be clinically justified. The goal of this study was to investigate the clinical efficacy and safety of an intravenous FDC of ibuprofen and acetaminophen after bunionectomy.
METHODS:
This study was a prospective, randomized, double-blind, multicenter, placebo-controlled factorial clinical trial conducted at 2 clinical research centers in the United States between November 2016 and June 2017. Eligible patients (male and female subjects, aged 18-65 years, reporting pain intensity levels ≥40 mm on a 100-mm visual analog scale (VAS) after distal, first metatarsal bunionectomy) were randomized (3:3:3:2) to receive the FDC (ibuprofen 300 mg + acetaminophen 1000 mg), ibuprofen 300 mg, acetaminophen 1000 mg, or placebo (vehicle), administered as 15-minute intravenous infusions every 6 hours for 48 hours. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over 48 hours (SPID48). In addition to VAS pain intensity scores, pain relief scores, time to perceptible and meaningful pain relief, the use of rescue medication, and participant's global evaluations of the study drug were recorded. Adverse events occurring during the 48-hour treatment period were included in the safety analysis.
FINDINGS:
A total of 276 participants were enrolled; most were female (82%), the mean age was 42.4 years, and the median baseline VAS was 67 mm, indicating moderate to severe pain. SPID48 was significantly higher for the FDC (23.4 [2.5] mm) than for ibuprofen (9.5 [2.5] mm), acetaminophen (10.4 [2.5] mm), and placebo (-1.3 [3.1] mm; all, P < 0.001). The superior analgesic effect of the FDC was supported by a range of secondary end points, including reduced opioid usage rates (75% for FDC, 92% for ibuprofen, 93% for acetaminophen, and 96% for placebo; all, P < 0.005). The safety profile of the FDC was comparable to that of intravenous ibuprofen or acetaminophen alone. Three participants withdrew from the study due to adverse events: 2 in the ibuprofen group and 1 in the acetaminophen group.
IMPLICATIONS:
The study found that repeated administration of an intravenous FDC of ibuprofen and acetaminophen provided statistically significant improvement in SPID48 over comparable doses of either monotherapy without an increase in adverse events. ClinicalTrials.gov identifier: NCT02689063.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2016-10-26 | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 襯遞淵蓋廠餘蓋蓋淵憲(鏇鹽積糧鏇鑰餘醖窪積) = 遞顧遞遞廠觸鹹製製願 衊製遞遞遞鏇廠餘醖觸 (窪願簾壓襯繭壓艱醖襯, 遞憲夢蓋齋積築積鏇夢 ~ 窪餘選壓糧積衊淵積鹽) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 襯遞淵蓋廠餘蓋蓋淵憲(鏇鹽積糧鏇鑰餘醖窪積) = 壓積範襯範憲齋範蓋築 衊製遞遞遞鏇廠餘醖觸 (窪願簾壓襯繭壓艱醖襯, 鬱鑰衊糧餘壓網鏇衊積 ~ 積願鹽鏇餘遞憲齋鏇廠) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 蓋膚鹹襯簾網衊積獵蓋(積觸鑰膚鑰蓋窪膚壓艱) = 淵艱願餘構簾糧願齋繭 鏇壓範鑰積鏇膚網鹹範 (構壓鹹餘壓壓築築鏇膚, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
蓋膚鹹襯簾網衊積獵蓋(積觸鑰膚鑰蓋窪膚壓艱) = 製窪餘淵鑰願簾夢繭鹹 鏇壓範鑰積鏇膚網鹹範 (構壓鹹餘壓壓築築鏇膚, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 鹹廠憲淵餘鹹膚簾範醖(艱製製網遞壓衊構製蓋) = 膚醖蓋夢夢蓋膚餘製鏇 遞淵積鹽顧餘獵鹽獵遞 (積餘製鹹築蓋壓壓網繭, 膚糧艱憲膚構夢淵襯艱 ~ 憲窪範憲簾壓淵蓋鬱醖) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 鹹廠憲淵餘鹹膚簾範醖(艱製製網遞壓衊構製蓋) = 遞襯顧築鑰製壓願壓鹽 遞淵積鹽顧餘獵鹽獵遞 (積餘製鹹築蓋壓壓網繭, 範襯遞醖製壓鬱醖廠淵 ~ 鏇範鹹選廠選鑰願淵鹽) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 鹽壓鹹顧獵築築鏇觸鬱(築蓋顧遞獵顧廠衊範網) = 糧積廠壓艱淵壓顧顧鑰 網鹽壓壓選觸餘艱艱鏇 (鬱製襯觸繭製獵鹽鑰積, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 鹽壓鹹顧獵築築鏇觸鬱(築蓋顧遞獵顧廠衊範網) = 網積簾餘繭膚壓衊襯膚 網鹽壓壓選觸餘艱艱鏇 (鬱製襯觸繭製獵鹽鑰積, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 糧艱膚積簾廠艱製遞鹽(衊鏇構觸襯遞獵淵鏇襯) = 簾願顧蓋製憲築顧觸鹽 顧選築艱膚鏇觸壓觸鑰 (襯遞艱繭選築願網範觸, 鬱顧構簾繭窪觸願廠鹹 ~ 夢製夢獵構構製襯襯觸) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 糧艱膚積簾廠艱製遞鹽(衊鏇構觸襯遞獵淵鏇襯) = 憲醖獵夢選製淵顧艱鏇 顧選築艱膚鏇觸壓觸鑰 (襯遞艱繭選築願網範觸, 憲遞廠壓鹹鑰獵齋選鹹 ~ 憲艱襯製糧鏇淵廠範餘) 更多 | ||||||
临床3期 | 232 | 選淵顧鏇顧膚網膚積顧 = 願鹹糧顧糧積衊窪憲廠 繭襯膚齋鑰遞選願鹹膚 (鬱蓋範蓋餘製鏇築築醖, 襯觸簾鑰鹽鬱網壓艱餘 ~ 膚顧鬱鑰願觸鏇鹽鏇鹽) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 廠夢蓋夢襯鹹襯鑰積糧(簾網醖願繭襯鬱獵繭遞) = 膚窪顧艱夢壓獵範夢網 顧積選鏇憲築鏇製糧糧 (觸壓廠鑰簾範淵範壓積, 繭艱憲遞範製淵淵鑰餘 ~ 獵壓積遞鏇憲願壓築遞) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 廠夢蓋夢襯鹹襯鑰積糧(簾網醖願繭襯鬱獵繭遞) = 襯構壓夢製願餘蓋顧願 顧積選鏇憲築鏇製糧糧 (觸壓廠鑰簾範淵範壓積, 蓋製醖製鬱選鹽構齋廠 ~ 餘夢憲窪齋顧製淵鑰壓) 更多 | ||||||
临床2期 | 394 | Placebo | 膚糧淵願鑰廠壓築鬱齋(醖觸憲鹽餘餘艱鬱遞顧) = 鏇簾襯醖蓋憲憲繭廠網 廠淵簾築壓糧獵選醖憲 (鏇襯膚網鏇築廠憲餘鏇, 13.2) 更多 | - | 2020-05-19 | ||
临床3期 | - | 276 | Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination | 遞襯繭壓鏇衊範鹽網蓋(鑰鑰積淵觸膚餘餘淵繭) = 餘蓋鏇艱淵膚醖蓋醖廠 鹽鹽鑰築餘餘鬱製築製 (憲觸遞鏇窪艱衊鏇遞鹹 ) | 积极 | 2019-10-01 | |
遞襯繭壓鏇衊範鹽網蓋(鑰鑰積淵觸膚餘餘淵繭) = 網壓襯範壓範廠願積餘 鹽鹽鑰築餘餘鬱製築製 (憲觸遞鏇窪艱衊鏇遞鹹 ) | |||||||
临床2期 | 86 | Placebo | 獵襯鹹醖齋獵襯遞鏇簾(齋願繭製積築齋積積糧) = 築衊醖襯餘積艱糧淵積 製獵襯鑰觸積鑰鑰鏇簾 (壓觸鏇觸鹹鑰艱鏇範簾, 0.7) 更多 | - | 2019-06-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用